REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Regenxbio's price to sales ratio was 2.6× on Nov 11, 2026, against 4.2× a year earlier. Over the last 5 years it ranged from 1.9× to 15.0×, with a median of 4.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.6× | −1.9 |
| 2025 | Dec 31, 2025 | 4.5× | −0.0 |
| 2024 | Dec 31, 2024 | 4.5× | −3.4 |
| 2023 | Dec 29, 2023 | 7.9× | +5.9 |
| 2022 | Dec 30, 2022 | 2.0× | −13.0 |
| 2021 | Dec 31, 2021 | 15.0× | +3.3 |
| 2020 | Dec 31, 2020 | 11.7× | −11.8 |
| 2019 | Dec 31, 2019 | 23.5× | +15.2 |
| 2018 | Dec 31, 2018 | 8.3× | −94.6 |
| 2017 | Dec 29, 2017 | 102.9× | +36.0 |
| 2016 | Dec 30, 2016 | 67.0× | −34.6 |
| 2015 | Dec 31, 2015 | 101.6× | – |
See a number that looks wrong?